A Phase IIa Prospective, Open-label, Multicenter Study to Determine the Pharmacokinetics (PK) and Safety and Tolerability of Astreonam-avibactam (ATM-AVI) for the Treatment of Complicated Intra-Abdominal Infections (cIAIs) in Hospitalized Adults
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Avibactam/aztreonam (Primary) ; Metronidazole
- Indications Intra-abdominal infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms REJUVENATE
- Sponsors AstraZeneca; Pfizer
- 16 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Nov 2017.
- 16 Feb 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
- 16 Dec 2016 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.